Prognostic scores and biomarkers in hematologic malignancies: current evidence and future perspectives
The advent of immunotherapy has profoundly transformed the therapeutic landscape of hematologic malignancies. A broad range of immune-based strategies, including immune checkpoint inhibitors and adoptive cell therapies based on both T cells and natural killer (NK) cells, have achieved unprecedented clinical outcomes in...